Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Pharmacokinetics of Two Randomized Trials Evaluating the Safety and Efficacy of Indinavir, Saquinavir and Lopinavir in Combination with Low-Dose Ritonavir: The MaxCmin1 and 2 Trials

Autor: Justesen, Ulrik S, Fox, Zoe, Pedersen, Court, Cahn, Pedro, Gerstoft, Jan, Clumeck, Nathan, Losso, Marcello, Peters, Barry, Obel, Niels, Castagna, Antonella, Dragsted, Ulrik B, Lundgren, Jens D, 1 and 2 trial groups, MaxCmin

Publikováno v: Justesen, U S, Fox, Z, Pedersen, C, Cahn, P, Gerstoft, J, Clumeck, N, Losso, M, Peters, B, Obel, N, Castagna, A, Dragsted, U B, Lundgren, J D & 1 and 2 trial groups, M 2007, ' Pharmacokinetics of two randomized trials evaluating the safety and efficacy of indinavir, saquinavir and lopinavir in combination with low-dose ritonavir : the MaxCmin1 and 2 trials ', Basic & Clinical Pharmacology & Toxicology, vol. 101, no. 5, pp. 339-344 . https://doi.org/10.1111/j.1742-7843.2007.00117.x

Udgivelsesdato: 2007-Nov Our objective was to identify possible differences in protease inhibitor plasma concentrations between and within three protease inhibitor regimens (indinavir, saquinavir and lopinavir all in combination with low-dose ritonav

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::df0b1a50023a9f4dd7e607ca58e6077e
https://doi.org/10.1111/j.1742-7843.2007.00117.x

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Factors Associated with the Development of Opportunistic Infections in HIV-1-Infected Adults with High CD4 ⁺ Cell Counts: A EuroSIDA Study.

Autor: Podlekareva, Daria, Mocroft, Amanda, Dragsted, Ulrik B., Ledergerber, Bruno, Beniowski, Marek, Lazzarin, Adriano, Weber, Jonathan, Clumeck, Nathan, Vetter, Norbert, Phillips, Andrew, Lundgren, Jens D.

Publikováno v: Journal of Infectious Diseases; 9/1/2006, Vol. 194 Issue 5, p633-641, 9p

A Randomized Trial to Evaluate Lopinavir/Ritonavir versus Saquinavir/Ritonavir in HIV-1-Infected Patients: The Maxcmin2 Trial

Autor: Belloso, W, Ivalo, S, Benetucci, J, Pugliese, D, Garone, D, Cahn, P, Krolewiecki, A, Casiro, A, Cassetti, I, Bologna, R, Duran, A, Toibaro, J, Rieger, A, Vago, B, Clumeck, N, Kabeya, K, Cooper, C, Dufresne, S, Lalonde, R, Walmsley, S, Gerstoft, J, Mathiesen, L, Nielsen, H, Obel, N, Pedersen, C, Lazzarin, A, Castagna, A, Bruun, J N, Gatell, J M, Arnaiz, J, Blaxhult, A, Flamholc, L, Gisslén, M, Vernazza, P, Bingham, J, Peters, B, Gazzard, B, Nelson, M, Johnson, M, Youle, M, Weber, J, Scullard, G, Brar, I, Bouzi, V, Brutus, A, Jayaweera, D T, Mogyoros, M, Rodwick, B M, Stein, D, Wiznia, A, Schwartz, R, Vandenberg-Wolf, M G, Tedaldi, E, Dragsted, Ulrik B, Gerstoft, Jan, Youle, Mike, Fox, Zoe, Losso, Marcello, Benetucci, Jorge, Jayaweera, Dushyantha T, Rieger, Armin, Bruun, Johan N, Castagna, Antonella, Gazzard, Brian, Walmsley, Sharon, Hill, Andrew, Lundgren, Jens D.

Publikováno v: Antiviral Therapy; August 2005, Vol. 10 Issue: 6 p735-743, 9p